Woodline Partners LP Raises Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Woodline Partners LP increased its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 69.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 849,477 shares of the biotechnology company's stock after acquiring an additional 348,983 shares during the period. Woodline Partners LP owned approximately 0.59% of Aurinia Pharmaceuticals worth $7,628,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of AUPH. Blue Trust Inc. grew its holdings in Aurinia Pharmaceuticals by 3,041.4% in the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock valued at $57,000 after purchasing an additional 6,174 shares during the period. Deutsche Bank AG grew its stake in Aurinia Pharmaceuticals by 54.8% in the 4th quarter. Deutsche Bank AG now owns 142,869 shares of the biotechnology company's stock valued at $1,283,000 after acquiring an additional 50,575 shares during the period. Atria Wealth Solutions Inc. purchased a new stake in Aurinia Pharmaceuticals in the 4th quarter worth $135,000. Arrowstreet Capital Limited Partnership acquired a new position in Aurinia Pharmaceuticals during the fourth quarter worth $9,662,000. Finally, Price T Rowe Associates Inc. MD raised its position in Aurinia Pharmaceuticals by 19.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 52,098 shares of the biotechnology company's stock worth $468,000 after acquiring an additional 8,350 shares during the period. Hedge funds and other institutional investors own 36.83% of the company's stock.

Insider Buying and Selling at Aurinia Pharmaceuticals

In related news, CEO Peter Greenleaf sold 195,593 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the completion of the sale, the chief executive officer now owns 1,953,892 shares of the company's stock, valued at approximately $15,631,136. This represents a 9.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Greg Keenan sold 12,239 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $97,912.00. Following the transaction, the insider now owns 161,789 shares in the company, valued at approximately $1,294,312. This represents a 7.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 343,898 shares of company stock worth $2,753,094. Corporate insiders own 4.30% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, March 27th.

Aurinia Pharmaceuticals Price Performance

AUPH stock traded down $0.19 during trading on Monday, hitting $8.08. The stock had a trading volume of 2,007,945 shares, compared to its average volume of 1,333,749. Aurinia Pharmaceuticals Inc. has a twelve month low of $5.11 and a twelve month high of $10.67. The company's 50-day moving average price is $8.02 and its two-hundred day moving average price is $8.28. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The stock has a market capitalization of $1.09 billion, a P/E ratio of -53.86 and a beta of 1.16.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its earnings results on Monday, May 12th. The biotechnology company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.08. Aurinia Pharmaceuticals had a negative return on equity of 4.41% and a negative net margin of 10.23%. The business had revenue of $62.47 million for the quarter, compared to the consensus estimate of $61.06 million. As a group, research analysts predict that Aurinia Pharmaceuticals Inc. will post 0.11 EPS for the current fiscal year.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.